Navigation Links
SemBioSys to present new data at American Diabetes Association,annual meeting

TSX symbol: SBS

CALGARY, June 20, 2007 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. , a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular disease, today announced that it will be presenting a scientific poster and abstract at the 67th Scientific Sessions of the American Diabetes Association (ADA) in Chicago. The Company's poster will disclose recent accomplishments in the development of a highly-scalable, low cost source of recombinant human insulin. Poster session presentations will take place at the McCormick Place Convention Center on Saturday June 23 from 6:00pm to 7:15 pm and on Monday June 25 from 12:00pm to 2:00pm. The poster and abstract are titled:

"Chemical and Biological Characterization of Recombinant Human Insulin Produced in Transgenic Plants." Abstract Number 0459-P by Joseph Boothe, Cory Nykiforuk, Elizabeth Murray, Philip Kuhlman, W. Brent Pollock, Amanda Bodero, Joseph Goren, Richard Keon, Nancy Markley, and Maurice Moloney.

About SemBioSys Genetics Inc. (www.sembiosys.com)

Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company developing insulin and other protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's lead candidate is recombinant human insulin produced in the plant host safflower, to serve the rapidly expanding global diabetes market and to supply insulin for inhalation and other alternative insulin delivery technologies. The Company's other protein-based pharmaceutical candidate is a cardiovascular drug called Apo AI. SemBioSys is also developing a series of non-pharmaceutical products addressing animal and aquaculture health, nutritional oils and human topical markets.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.

CONTACT: SemBioSys Genetics Inc., Mr. Andrew Baum, President and ChiefExecutive Officer, Phone: (403) 717-8767, Fax: (403) 250-3886, E-mail:, Internet: www.sembiosys.com; Investor Relations, RossMarshall, The Equicom Group Inc., Phone: (416) 815-0700 (Ext. 238), Fax:(416) 815-0080, E-mail: bauma@sembiosys.com rmarshall@equicomgroup.com

Ticker Symbol: (Toronto:SBS.)

Terms and conditions of use apply
Copyr ight © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Pharmexa A/S (DK) - Pharmexa presents data from influenza program
4. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
5. CYT003-QbG10 to treat allergy to be presented at the Congress of the European Academy of Allergology and Clinical Immunology (EAACI), June 9-13, 2007
6. Data to be presented at AAN Meeting -Study results of drug candidate for MS
7. Amsterdam Molecular Therapeutics BV to present preclinical proof-of-concept data on its gene therapy AMT-020 to treat acute intermittent porphyria
8. Santaris Pharma presents positive preclinical data on SPC2996 at the American Association for Cancer Research
9. Data supporting three Antisoma programmes presented at AACR
10. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
11. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
Breaking Medicine Technology:
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th ... Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised ... have been wounded in battle and their families. Venture Construction Group is a 2016 ...
Breaking Medicine News(10 mins):